Nirsevimab (Beyfortus) 50 mg Remains Open for Ordering 

sgh acting co header

To: Maine Immunization Program Providers

From: Maine Immunization Program

Subject: Nirsevimab (Beyfortus) 50 mg Remains Open for Ordering 

Date: October 15, 2024

 

he Maine Immunization Program is pleased to announce that nirsevimab (Beyfortus) 50 mg for infants will remain open for ordering. This week’s allocation will only be available for ordering from Tuesday, October 15, 2024, to close of business on Friday, October 18, 2024, through ImmPact to all enrolled Vaccines for Children (VFC) providers. Ordering will remain available at a minimum quantity of 5 doses and a maximum quantity of 10 doses per site. Due to weekly allocation constraints, enrolled provider sites will not be able to order their full season supply at this time.   

Nirsevimab 100 mg doses remain available to all enrolled VFC providers for order at a minimum quantity of 5 doses and maximum quantity of 100 doses per order.  

**All orders MUST be placed separate from regular vaccine orders. Orders placed with other vaccines in ImmPact will be denied. 

All remaining nirsevimab products in the State of Maine from the 2023-2024 season have an expiration date ending in 2025. Any remaining inventory from last season should continue to be stored at appropriate temperature and used first at the start of the 2024-2025 RSV season. 

For any questions, please contact the Maine Immunization Program at (207) 287-3746 or email ImmunizeME.DHHS@maine.gov